FDA approves Lynparza for metastatic breast cancer
12 January 2018 16:10 GMT LYNPARZA APPROVED BY US FDA IN GERMLINE BRCA-MUTATED METASTATIC BREAST CANCER Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer Lynparza reduced the risk of disease progression or death by 42% compared to standard of care chemotherapy AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has approved Lynparza (olaparib), for use in patients with deleterious or suspected deleterious germline BRCA-